相关实验视频

Updated: Sep 15, 2025

Cecal Ligation and Puncture-induced Sepsis as a Model To Study Autophagy in Mice

Cecal Ligation and Puncture-induced Sepsis as a Model To Study Autophagy in Mice

Published on: February 9, 2014

通过PI3K/AKT信号通路,ALA减轻了败血症小鼠的肝损伤

Yuqing Song¹, Yuanrong Mao², Qingqing Sui¹

¹Department of Pain The First Hospital of China Medical University Shenyang Liaoning People's Republic of China.

Food science & nutrition

|July 14, 2025

概括

阿尔法-酸 (ALA) 保护小鼠免受败血症引起的肝损伤. ALA治疗激活PI3K/AKT通路,减少肝细胞亡和改善功能,为败血症提供潜在的治疗策略.

科学领域:

生物医学科学生物医学科学
病理学病理学病理学
药理学药理学是指药理学的学科.

背景情况:

败血症是一种严重的疾病,导致全身炎症和多器官功能障碍,尤其是肝损伤.
阿尔法-酸 (ALA) 具有抗氧化和抗炎性质,在败血症管理中显示出潜力.
PI3K/AKT信号通路在细胞对败血症和损伤的反应中起作用.

研究的目的:

为了研究阿尔法脂酸 (ALA) 在败血症小鼠模型中对肝损伤的保护作用.
为了确定ALA是否调节了在败血症引起的肝损伤中的PI3K/AKT信号通路.
探索ALA作为毒症相关的肝损伤的潜在治疗策略.

主要方法:

在小鼠中诱导败血症是使用结和穿孔 (CLP) 模型.
鼠被用ALA治疗或作为对照.
肝功能,细胞亡和PI3K/AKT通路蛋白质表达被评估使用生物化学测试,西式涂抹和免疫组织化学.

主要成果:

在败血症小鼠中,ALA治疗显著降低了肝细胞亡.
与对照组相比,服用ALA改善了肝功能关键指标.
ALA 增强了在败血性肝脏组织中PI3K/AKT信号通路的激活.
组织病理学检查显示,在接受ALA治疗的组中,肝脏组织损伤减少.

结论:

阿尔法-酸 (ALA) 在毒症的小鼠模型中显示出显著的肝保护作用.
通过激活PI3K/AKT信号通路,ALA可以缓解败血症引起的肝损伤.
这些发现表明,ALA具有治疗败血症及其相关肝损伤的临床潜力.

关键词:

在PI3K/AKT中使用.阿尔法-利波酸是什么阿尔法-利波酸抗氧化剂是一种抗氧化剂.灭症 (apoptosis) 是一种死亡的过程.这是一种血症.

更多相关视频

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Published on: May 10, 2024

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...